fashion -WSS

fashion

author：hotspot 2025-10-01 02:15:47 - browse：85434

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Ohio train derailment: Experts on toxic chemical risks

knowledge

WSS

HHS suspends federal funding for EcoHealth Alliance

Cholera vaccine supplies dangerously low, outbreaks surging

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Readout Newsletter: Beam, Prozac, "TechBio" and more

Readout Newsletter: Beam, Prozac, "TechBio" and more

Color Health wants to make cancer screenings convenient

hotspot

fashion

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

ChatGPT in medicine: STAT answers readers' burning questions

Using force crossed my mind when examining a defiant young patient

Peter Hotez and the public health issue of online harassment

WuXi Biologics beefs up its lobbying operation

Dobbs anniversary: the lost opportunity of abortion as health care

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Medical records are filled with copy

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

leisure time

Cholera vaccine supplies dangerously low, outbreaks surging

Pfizer is about to make a big push in cancer. Will investors listen?

Using force crossed my mind when examining a defiant young patient

Novo Nordisk testing Wegovy against alcohol

Pfizer is about to make a big push in cancer. Will investors listen?

Children’s Hospital revives plan for pedestrian bridge

Wikipedia

knowledge

Wikipedia

focus